Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
Generic vs name brand drugs quiz
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Recommended: Generic vs name brand drugs quiz
Generic drug savings are widely recognized as a long-term solution to rising health costs. The 2014 Express Scripts Drug Trend Report shows that since 2008, the price of brand drugs has almost doubled but the price of generic drugs has been cut roughly in half.6 Purchasing generic versions instead of their brand-name equivalent drugs can provide substantial savings, not only for state and local governments and Medicaid programs, but also for health insurers, employers, employees, and direct pay patients.11 The need for prescriptions typically increases with age and the savings made possible by generic drug use among older adults and seniors are critical to sustaining affordable health care.6
There are several factors affecting generic drug
There seems to be no law protecting patients from the price increases that these big pharmaceutical companies are making. Marcia Angell, is an American physician, author, and the first woman to serve as editor-in-chief of the New England Journal of Medicine. In chapter 10 of her book, The Truth About the Drug Companies, she talks about stretching out the idea on monopoly. Patents makes it illegal for a specific set amount of time for competitors to sell the same/similar drugs. Once the patent is over, when the company loses its rights to a drug, the Food and Drug Administration (FDA) arranges for the generic version of the drugs made by a different company to go out on the market. When there is only one generic brand on the market, the cost may not be as cheap because the generic brand and the brand name shadow prices. This keeps the generic version just beneath the price of the brand name. Although the generic is not that much cheaper than the brand name, in the course of one year, the brand name company will lose hundred of millions of dollars due to generic drugs. From an economic point of view,
Depending on which insurance consumers have can affect how much out of cost or co-payments consumers will have to pay. Insurance can cover either a large portion of the cost of prescriptions or eliminate the $200.00 co-payment that EpiPens require. Some insurances may be able to perform both. Adam Fein, president of the Pembroke Consulting, states that “some insurers may have negotiated deals with Mylan that end up making the brand-name cheaper than the generic” (Drake 3). If this is the case, some insurances would rather have consumers purchase the name-brand version of the EpiPen rather than the generic version that is offered. Mylan Pharmaceuticals offers a coupon that takes off up to $100.00 per prescription. This coupon is limited to only three prescriptions of two-pack cartons, however. This would leave the total of the EpiPens to $500.00 before taxes. Mylan Pharmaceuticals also offers the Mylan’s Patient Assistance Program which “allows patients, whom are without insurance, eligibility to apply for free EpiPens” (Drake 5). Mylan Pharmaceuticals now offers no-copayment fees to those who use a savings card provided by Mylan when purchasing the name-brand
(II) The enacting of Medicare Part D in 2006 only helped to fuel America’s hunger for prescription medication. In 2003, President George W. Bush announced and signed the Medicare Prescription Drug, Improvement, and Modernization Act (also known as the Medicare Modernization Act, or MMA) on December 8th. The roughly $400 billion dollar measure was marketed to the American public as something that will provide care for the millions of senior citizens who, at the time, were struggling to afford prescription medication. This was the largest development of Medicare since 1965, which is when the program was initially created, and gave hope to those wishing for positive medical reform. According to title XI of the “Medicare Prescription Drug, Improvement, and Modernization Act of 2003”, the most significant change will be the affordability of prescription drugs by implementing the importation of drugs from Canada, along with necessary safety measures, in order to lessen the cost (United States Congress, 832). For those who were in retirement homes and lacked a steady income, the affordability of drugs was often a deciding factor in the decision to seek medical attention and the idea that those individuals ceased to live simply because they lacked the funds tugged at the heartstrings of many Americans.
Why do consumers purchase specific drugs for various ailments, sicknesses or diseases they might have? Why do physicians prescribe certain drugs over competitive drugs that may be available to the public? Why is it that most of us can easily name specific drugs that fit the many ailments of today’s society? On the surface the answer might be as simple as good TV advertising or radio commercials or even internet adds. The truth of matter is the major pharmaceutical manufacturers own the patents on these drugs and this gives them all of the marketing budget and muscle they need to promote the drug and control the pricing. The incentives for larger pharmaceutical companies are very enticing and as a result, they don’t mind spending the time in clinical trials and patent courts to get their drugs approved. Some will even get patents on the process by which the drug is manufactured, ensuring that no competitor can steal the drug or the process. This protects their large financial investment and nearly guarantees a large return for their investors. Many consumer rights groups claim this is nothing more than legalizing monopolies for the biggest manufacturers.
This is definitely a problem for consumers because they can have ties with the pharmaceutical and they have the ability to evoke the best interests for their company when pricing drugs. According to the drug makers and the intermediaries, the higher cost are needed to pay of rebates and providing discounts for insurers and employers. Despite providing incentives to those with insurance, this alienates those who have little to no insurance, they are left to burden the higher drug prices. In the U.S., there isn’t a checks and balances system when it comes to drug pricing like in the U.K. therefore some critics do not blame Mylan for raising the price for these drugs. Making and testing for innovative medicines requires years of research, which means money. Therefore, I do understand that drug makers, the pharmaceutical company and its investors want to get paid for the amount of time and money that they put into their new drug. However, I believe that they need to find that particular medium that helps the people especially those who are less fortunate and in need for this life-saving medication while being able to make a
No matter what type of coverage you have, you are going to save money on your health insurance if you always opt for generic drugs. Experts agree that generic versions are identical to brand names in their effectiveness, and are typically widely
The question, however, is whether or not such drug coverage is a worthwhile project to undertake. Is the problem indeed serious enough to call for the type of reform that the candidates are proposing? Medicare is already a very costly program to keep up, and adding prescription-drug coverage would increase these costs even more. In order to fund this project, there will need to be a tax hike. Should taxpayers subsidize this prescription-drug benefit? Is there a good reason why this redistribution should take place? What are the benefits and costs of this proposal? These and other questions will be addressed in this paper as we examine the following topics: the need for senior citizens to have prescription-drug coverage, the political rhetoric involved with this issue, the projected shortfall in the budget of the Medicare program, and who really would benefit if a prescription-drug benefit was added to Medicare.
In the business of drug production over the years, there have been astronomical gains in the technology of pharmaceutical drugs. More and more drugs are being made for diseases and viruses each day, and there are many more drugs still undergoing research and testing. These "miracle" drugs are expensive, however, and many Americans cannot afford these prices.
Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.
According to the Food and Drug Administration (FDA), 158 billion dollars was saved by Americans in 2010 simply by purchasing FDA-approved generic drugs instead of brand-name drugs. At that time, generic drugs cost on average 80-85% less than the brand-name medication with eight out ten prescriptions being filled with generic drugs. The reason generic drugs are less expensive than their brand-name counterpart is because the FDA does not require the manufacturers to repeat clinical trials for safety and efficacy and these drugs are typically not advertised, marketed, or promoted (Food and Drug Administration, 2013).
The United States spends more per capita on health care than any other country, with the percentage of gross domestic product dedicated to health care doubling from 9% in 1980 to 18% in 2011(Kesselheim,). One of the contributors to health care inflation is prescription drugs. Pharmaceuticals account for about 10% of total health care costs, spending on pharmaceuticals is poised to swell in upcoming years as a result of the increasing prices of complex specialty medicines (Kesselheim). Name brand drugs are going to have to be set at higher prices, in order for pharmaceutical companies to receive a profit. If the patient has full coverage on a medication, there is a greater chance that medication will be taken, although it may not be
The rise in cost of prescription drugs affects all sectors of the health care industry, including private insurers, public programs, and patients. Spending on prescription drugs continues to be an important health care concern, particularly in light of rising pharmaceutical costs and the aging population. Prescription drugs have grown to become an essential component of health care. For millions of Americans, prescription drugs are necessary to their health and ability to function in society. While prescriptions are a relatively small portion of overall health spending, they are a main reason for certain health spending trends, growing almost twice as fast all other health services in recent years. Prescription costs can be the costliest expense in your budget, especially if you are on a fixed income. The wealthy can easily afford their medications, but for an increasing population such as the elderly, choosing among purchasing medication, paying bills, or buying food is a real concern.
Even with health care coverage being at the tips of our finger, we still are positioned with the question how will I pay for this, as well as where this money comes from. Reports have indicated that the United States has spent “$2.2 trillion for health care in 2007, which was an increase of 6.7% from $2.1 trillion in 2006” (Wexler). This revenue comes to all of our taxable expenses, which in turn trickles down to the Affordable Care Act. Receiving any medical care, is expensive in general, from staffing of the hospitals to creating the medication that someone needs to further their lives. Wexler addresses the increase of medication production. ” One of the fastest-growing components of health care is the market for prescription drugs. In 2006 Americans spent $216.7 billion on prescription medication—this was an 8.5% increase from $199.7 billion in 2005” (Wexler) The increase can be a good way to think of how the money is spent. We fund the projects that in turn create fundamental medications to help those who need
There are three issues when it comes to the health care cost rising. The first is the rising cost in prescription drugs. The second area of rising cost is the increased technologies when it comes to the medical industry. The third problem is the aging population. Prescription drugs are the area of the fastest growing health care expense, and it is projected to grow at 20 to 30 percent each year over the next several years. There are many newer, more expensive drugs on the market, and the use of these prescriptions is exploding. In addition, with so much television advertising, many consumers ask their doctors for expensive, brand name drugs when there may actually be a generic drug that works just as well.
The aging of the baby boomer generation along with the increasing longevity of life expectancies are evolving the demographics of the United States’ society. Older adults account for a much larger percentage of the population than ever before and it is expected that by 2030, one in every five Americans will be eligible for Medicare (Elder Workforce Alliance [EWA], 2012). As Americans are living longer they are also at a greater risk of chronic illness. This shift commands attention and analysis of our current health care system to better meet the needs of this growing population.